Intervention Review

You have free access to this content

Haloperidol versus placebo for schizophrenia

  1. Clive E Adams1,*,
  2. Hanna Bergman2,
  3. Claire B Irving1,
  4. Stephen Lawrie3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 15 NOV 2013

Assessed as up-to-date: 15 MAY 2012

DOI: 10.1002/14651858.CD003082.pub3


How to Cite

Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD003082. DOI: 10.1002/14651858.CD003082.pub3.

Author Information

  1. 1

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  2. 2

    Enhance Reviews Ltd, Wantage, UK

  3. 3

    University of Edinburgh, Department of Psychiatry, Edinburgh, Scotland, UK

*Clive E Adams, Cochrane Schizophrenia Group, The University of Nottingham, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road,, Nottingham, NG7 2TU, UK. clive.adams@nottingham.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 15 NOV 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 1 Global state: 1a. Overall improvement: No marked global improvement.
[Analysis 1.2]
Analysis 1.2. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 2 Global state: 1b. Overall improvement: Average change in CGI-S score (up to 6 weeks; high = poor).
[Analysis 1.3]
Analysis 1.3. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 3 Global state: 2. Hospital discharge: Not discharged from hospital (> 6-24 weeks).
[Analysis 1.4]
Analysis 1.4. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 4 Global state: 3. Relapse (< 52 weeks).
[Analysis 1.5]
Analysis 1.5. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 5 Global state: 4. Leaving the study early.
[Analysis 1.6]
Analysis 1.6. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 6 Mental state: 1. No clinical improvement (< 20% reduction in BPRS score; up to 6 weeks).
[Analysis 1.7]
Analysis 1.7. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 7 Mental state: 2a. General symptoms: Average BPRS total score (up to 6 weeks; high = poor).
[Analysis 1.8]
Analysis 1.8. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 8 Mental state: 2b. General symptoms: Average change in PANSS total score (up to 6 weeks; high = poor).
[Analysis 1.9]
Analysis 1.9. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 9 Mental state: 3. Positive symptoms: Average change in PANSS positive score (up to 6 weeks; high = poor).
[Analysis 1.10]
Analysis 1.10. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 10 Mental state: 4. Negative symptoms: Average change in PANSS negative score (up to 6 weeks; high = poor).
[Analysis 1.11]
Analysis 1.11. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 11 Mental state: 5. Mood: Average change in CDS score (up to 6 weeks; high = poor).
[Analysis 1.12]
Analysis 1.12. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 12 Adverse effects: 1a. Movement disorders: Extrapyramidal symptoms.
[Analysis 1.13]
Analysis 1.13. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 13 Adverse effects: 1b. Movement disorders: Tardive dyskinesia.
[Analysis 1.14]
Analysis 1.14. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 14 Adverse effects: 1c. Movement disorders: Average changes scores (various scales; up to 6 weeks).
[Analysis 1.15]
Analysis 1.15. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 15 Adverse effects: 2. Other CNS.
[Analysis 1.16]
Analysis 1.16. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 16 Adverse effects: 3. Cardiovascular effects.
[Analysis 1.17]
Analysis 1.17. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 17 Adverse effects: 4. Other adverse effects.
[Analysis 1.18]
Analysis 1.18. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 18 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Global state: Overall improvement: No marked global improvement, > 6-24 weeks (clinician rated).
[Analysis 1.19]
Analysis 1.19. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 19 SUBGROUP ANALYSIS: 2. 18-65 YEARS vs < 18 YEARS: Global state: Overall improvement: No marked global improvement, > 6-24 weeks (clinician rated).
[Analysis 1.20]
Analysis 1.20. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 20 SUBGROUP ANALYSIS: 3. ACUTE vs CHRONIC: Global state: Overall improvement: No marked global improvement, > 6-24 weeks (clinician rated).
[Analysis 1.21]
Analysis 1.21. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 4. LOW DOSE vs MEDIUM TO HIGH DOSE.
[Analysis 1.22]
Analysis 1.22. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 5. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA.
[Analysis 1.23]
Analysis 1.23. Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 23 SENSITIVITY ANALYSIS: 1. ASSUMPTIONS FOR MISSING DATA vs NO ASSUMPTIONS FOR MISSING DATA: Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated).